β-Caryophyllene Inhibits Cell Proliferation through a Direct Modulation of CB2 Receptors in Glioblastoma Cells
Open Access
- 22 April 2020
- Vol. 12 (4), 1038
- https://doi.org/10.3390/cancers12041038
Abstract
Glioblastomas are aggressive cancers characterized by uncontrolled proliferation and inflammation. b-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that showed an important anti-inflammatory effect through the interaction of CB2 and peroxisome proliferator-activated receptor gamma (PPARg) receptors. BCP effects were investigated in an in vitro model of glioblastoma. U-373 and U87, derived from a human glioblastoma, and human glioma stem-like cells (GSCs) were treated with BCP at different doses and time-points. AM360, a specific CB2 antagonist, was added 2 h before BCP treatment. BCP showed a significant anti-proliferative effect, reducing cell viability, inhibiting cell cycle, and increasing apoptosis, as demonstrated by Tunel assay, caspase-3 and caspase -9 activation. In addition, the pro-apoptotic BAX expression was increased, whereas the anti-apoptotic Bcl-2 expression was reduced. Treatment with BCP decreased Beclin-1, LC3 and p62/SQSTM1 expression, indicating a possible switch of autophagy to apoptosis. BCP’s anti-inflammatory effect was demonstrated by NF-κB reduction, PPARg activation and TNF-a decrease; BCP significantly reduced Jun N-Terminal Kinase (JNK) expression as a consequence of TNF-α inhibition. AM360 abrogated BCP effects, thus demonstrating the BCP mechanism of action through the CB2 receptor. These findings let us hypothesize that BCP may act as a tumor suppressor in glioblastoma, acting on CB2 receptor and modulating JNK.This publication has 28 references indexed in Scilit:
- Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterationsClinical and Translational Oncology, 2019
- Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomasJournal of Neuro-Oncology, 2013
- Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in GlioblastomaCancer Cell, 2013
- Interleukins in glioblastoma pathophysiology: implications for therapyBritish Journal of Pharmacology, 2013
- Cannabinoid Signaling in Glioma CellsAdvances in experimental medicine and biology, 2012
- The NF- B Family of Transcription Factors and Its RegulationCold Spring Harbor Perspectives in Biology, 2009
- Glioblastoma multiforme: a review of where we have been and where we are goingExpert Opinion on Investigational Drugs, 2009
- Beta-caryophyllene is a dietary cannabinoidProceedings of the National Academy of Sciences of the United States of America, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggressionProstaglandins, Leukotrienes & Essential Fatty Acids, 2002